296 related articles for article (PubMed ID: 26141812)
1. Efficacy and safety of tazobactam/piperacillin as an empirical treatment for the patients of adult and child with febrile neutropenia in Japan.
Tamura K; Akiyama N; Kanda Y; Saito M
J Infect Chemother; 2015 Sep; 21(9):654-62. PubMed ID: 26141812
[TBL] [Abstract][Full Text] [Related]
2. Meropenem versus piperacillin-tazobactam as empiric therapy for febrile neutropenia in pediatric oncology patients.
Sezgin G; Acipayam C; Ozkan A; Bayram I; Tanyeli A
Asian Pac J Cancer Prev; 2014; 15(11):4549-53. PubMed ID: 24969883
[TBL] [Abstract][Full Text] [Related]
3. Piperacillin/tazobactam monotherapy versus piperacillin/tazobactam plus amikacin as initial empirical therapy for febrile neutropenia in children with acute leukemia.
Zengin E; Sarper N; Kılıç SC
Pediatr Hematol Oncol; 2011 May; 28(4):311-20. PubMed ID: 21524156
[TBL] [Abstract][Full Text] [Related]
4. Monotherapy with piperacillin/tazobactam versus cefepime as empirical therapy for febrile neutropenia in pediatric cancer patients: a randomized comparison.
Corapcioglu F; Sarper N; Zengin E
Pediatr Hematol Oncol; 2006; 23(3):177-86. PubMed ID: 16517534
[TBL] [Abstract][Full Text] [Related]
5. Comparison between piperacillin/tazobactam and cefepime monotherapies as an empirical therapy for febrile neutropenia in children with hematological and malignant disorders: A prospective, randomized study.
Sano H; Kobayashi R; Suzuki D; Kishimoto K; Yasuda K; Kobayashi K
Pediatr Blood Cancer; 2015 Feb; 62(2):356-358. PubMed ID: 25251104
[TBL] [Abstract][Full Text] [Related]
6. Piperacillin-tazobactam as a cost effective monotherapy in febrile neutropenia.
Fasih S; Siddiqui N; Muza N; Hannan A; Sarwar S; Shafi A; Athar S
J Ayub Med Coll Abbottabad; 2013; 25(3-4):19-22. PubMed ID: 25226731
[TBL] [Abstract][Full Text] [Related]
7. A randomized, open-label, multicenter comparative study of the efficacy and safety of piperacillin-tazobactam and cefepime for the empirical treatment of febrile neutropenic episodes in patients with hematologic malignancies.
Bow EJ; Rotstein C; Noskin GA; Laverdiere M; Schwarer AP; Segal BH; Seymour JF; Szer J; Sanche S
Clin Infect Dis; 2006 Aug; 43(4):447-59. PubMed ID: 16838234
[TBL] [Abstract][Full Text] [Related]
8. A clinical evaluation of efficacy and safety of cefepime monotherapy versus piperacillin-tazobactam in patients of paediatric age group with febrile neutropenia in a tertiary care centre of north India.
Aamir M; Abrol P; Sharma D; Punia H
Trop Doct; 2016 Jul; 46(3):142-8. PubMed ID: 26612093
[TBL] [Abstract][Full Text] [Related]
9. A comparison of the efficacy of piperacillin-tazobactam and cefoperazone-sulbactam therapies in the empirical treatment of patients with febrile neutropenia.
Aynioglu A; Mutlu B; Hacihanefioglu A
Rev Esp Quimioter; 2016 Apr; 29(2):69-75. PubMed ID: 26888338
[TBL] [Abstract][Full Text] [Related]
10. Piperacillin-tazobactam versus carbapenem therapy with and without amikacin as empirical treatment of febrile neutropenia in cancer patients: results of an open randomized trial at a university hospital.
Oztoprak N; Piskin N; Aydemir H; Celebi G; Akduman D; Keskin AS; Gokmen A; Engin H; Ankarali H
Jpn J Clin Oncol; 2010 Aug; 40(8):761-7. PubMed ID: 20427546
[TBL] [Abstract][Full Text] [Related]
11. Comparison of piperacillin tazobactam and cefoperazone sulbactam monotherapy in treatment of febrile neutropenia.
Karaman S; Vural S; Yildirmak Y; Emecen M; Erdem E; Kebudi R
Pediatr Blood Cancer; 2012 Apr; 58(4):579-83. PubMed ID: 21674768
[TBL] [Abstract][Full Text] [Related]
12. Piperacillin-tazobactam vs. imipenem-cilastatin as empirical therapy in hematopoietic stem cell transplantation recipients with febrile neutropenia.
Jing Y; Li J; Yuan L; Zhao X; Wang Q; Yu L; Zhou D; Huang W
Clin Transplant; 2016 Mar; 30(3):263-9. PubMed ID: 26701371
[TBL] [Abstract][Full Text] [Related]
13. Monotherapy with piperacillin/tazobactam versus combination therapy with ceftazidime plus amikacin as an empiric therapy for fever in neutropenic cancer patients.
Hess U; Böhme C; Rey K; Senn HJ
Support Care Cancer; 1998 Jul; 6(4):402-9. PubMed ID: 9695210
[TBL] [Abstract][Full Text] [Related]
14. Imipenem-cilastatin versus piperacillin-tazobactam as monotherapy in febrile neutropenia.
Vural S; Erdem E; Gulec SG; Yildirmak Y; Kebudi R
Pediatr Int; 2010 Apr; 52(2):262-7. PubMed ID: 19744230
[TBL] [Abstract][Full Text] [Related]
15. Piperacillin/tazobactam plus ceftazidime versus sulbactam/ampicillin plus aztreonam as empirical therapy for fever in severely neutropenic pediatric patients.
Kobayashi R; Sato T; Nakajima M; Kaneda M; Iguchi A
J Pediatr Hematol Oncol; 2009 Apr; 31(4):270-3. PubMed ID: 19346879
[TBL] [Abstract][Full Text] [Related]
16. Meropenem plus amikacin versus piperacillin-tazobactam plus netilmicin as empiric therapy for high-risk febrile neutropenia in children.
Aksoylar S; Cetingül N; Kantar M; Karapinar D; Kavakli K; Kansoy S
Pediatr Hematol Oncol; 2004 Mar; 21(2):115-23. PubMed ID: 15160510
[TBL] [Abstract][Full Text] [Related]
17. [Clinical effects and safety of piperacillin/tazobactam in treating neutropenic febrile patients with malignant hematopathy].
Lu KY; Jia JS; Li J; Wang C; Wu DP; Hu LD; Huang XJ
Zhonghua Yi Xue Za Zhi; 2009 Jan; 89(1):41-4. PubMed ID: 19489243
[TBL] [Abstract][Full Text] [Related]
18. Piperacillin/tazobactam versus cefepime for the empirical treatment of pediatric cancer patients with neutropenia and fever: a randomized and open-label study.
Uygun V; Karasu GT; Ogunc D; Yesilipek A; Hazar V
Pediatr Blood Cancer; 2009 Oct; 53(4):610-4. PubMed ID: 19484759
[TBL] [Abstract][Full Text] [Related]
19. Piperacillin-tazobactam monotherapy in high-risk febrile and neutropenic cancer patients.
Viscoli C; Cometta A; Kern WV; Bock R; Paesmans M; Crokaert F; Glauser MP; Calandra T;
Clin Microbiol Infect; 2006 Mar; 12(3):212-6. PubMed ID: 16451406
[TBL] [Abstract][Full Text] [Related]
20. Cefepime plus amikacin versus piperacillin-tazobactam plus amikacin for initial antibiotic therapy in haematology patients with febrile neutropenia: results of an open, randomized, multicentre trial.
Sanz MA; López J; Lahuerta JJ; Rovira M; Batlle M; Pérez C; Vázquez L; Julià A; Palau J; Gutiérrez M; Capote FJ; Ramos F; Benlloch L; Larrea L; Jarque I;
J Antimicrob Chemother; 2002 Jul; 50(1):79-88. PubMed ID: 12096010
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]